Targeting NG2/CSPG4 to Slow Tumor Growth in Brain and Skin Cancers
Author Information
Author(s): Wang Jian, Svendsen Agnete, Kmiecik Justyna, Immervoll Heike, Skaftnesmo Kai Ove, Planagumà Jesús, Reed Rolf Kåre, Bjerkvig Rolf, Miletic Hrvoje, Enger Per Øyvind, Rygh Cecilie Brekke, Chekenya Martha
Primary Institution: University of Bergen, Bergen, Norway
Hypothesis
Does targeting the NG2/CSPG4 proteoglycan inhibit tumor growth and angiogenesis in glioblastoma and melanoma models?
Conclusion
Targeting NG2 significantly reduced tumor growth and angiogenesis in preclinical models of glioblastoma and melanoma.
Supporting Evidence
- NG2 overexpression in GBM cells led to increased tumor growth and angiogenesis.
- Knockdown of NG2 reduced tumor proliferation and increased cell death in melanoma models.
- Targeting NG2 normalized vascular function and reduced edema in GBM xenografts.
Takeaway
Scientists found that a protein called NG2 helps tumors grow and spread, so they tried to block it to see if it would make the tumors smaller.
Methodology
The study used xenograft models of glioblastoma and melanoma to assess the effects of NG2 knockdown on tumor growth and angiogenesis.
Limitations
The study did not find a significant difference in overall survival despite reduced tumor growth, possibly due to the presence of multiple invasive tumor lesions.
Statistical Information
P-Value
p<0.0005
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website